Given the numerous properties of GLP-1, this reduction likely affects inflammatory processes in the mucosa and disease-related symptoms on multiple levels, and therefore, should be considered a therapeutic target in inflammatory bowel diseases. This evidence concerns the gene GLP1R and inflammatory bowel disease.